Suppr超能文献

血栓形成和栓塞的血管内治疗

Endovascular Treatment of Thrombosis and Embolism.

作者信息

Goktay Ahmet Yigit, Senturk Cagin

机构信息

Interventional Radiology, Dokuz Eylul University Medical School Hospital, Izmir, Turkey.

Neurointerventional Radiology Division, Department of Radiological Sciences, University of California Irvine, School of Medicine, Orange, CA, USA.

出版信息

Adv Exp Med Biol. 2017;906:195-213. doi: 10.1007/5584_2016_116.

Abstract

Deep venous thrombosis (DVT) is a common disorder with a significant mortality rate. Successful endovascular treatment of acute DVT is most likely to be achieved in patients with recently formed thrombus, (<10-14 days) with acute iliofemoral DVT. Endovascular treatment options include: Catheter-directed thrombolysis (CDT), pharmacomechanical catheter-directed thrombolysis (PCDT), percutaneous aspiration thrombectomy (PAT), vena cava filter protection, venous balloon dilatation and venous stent implantation. Current practice shows strong clinical tendency for the use of PCDT with or without other endovascular methods and an individualized approach for each DVT patient. PMT has not received general acceptance because of the associated risk of PE and damage to venous valves caused by thrombectomy devices. PAT is most commonly used as an adjunctive endovascular technique like balloon maceration to fragment thrombus, balloon angioplasty, stent implantation and vena cava filter placement. Interventional endovascular therapies for DVT have the potential to provide PE protection and prevention of PTS. Patient centered individualized approach for endovascular DVT treatment is recommended to optimize the ideal clinical result.Acute stroke is the leading cause of death for people above the age of 60 and the fifth leading cause in people aged 15-59. Mortality during the first 30 days of ischemic stroke is 20 % and 30 % of survivors will remain permanently disabled. Acute stroke patients within the therapeutic window must receive IVrtPA unless there is a contraindication. In case of contraindication to IVrtPA or for patients out of the therapeutic window for thrombolytics, standart of care is the intraarterial treatment. Patients have to be transferred to a comprehensive stroke center with capacity of dedicated neurovascular imaging and interventional neuroradiology. Noncontrast head CT that is used to rule out hemorrhage is followed by imaging studies dedicated to show if there is reasonable penumbra to save. Intraarterial thrombolysis has the main advantage of extended therapy window, earlier and more efficient recanalization and less risk of hemorrhage due to lower doses of thrombolytics. Mechanical thrombectomy has several advantages over IV/IA fibrinolysis including faster recanalization and less risk of hemorrhage especially in large artery occlusions. ASA guidelines recommend choosing stent retrievers over other devices for mechanical thrombectomy. Better recanalization rates and less infarct volume after mechanical thrombectomy result in higher numbers of functionally independent patients compared with other treatments. Two landmark studies that were published recently, SWIFT PRIME and MR CLEAN, showed that IA treatment especially with the new stent retrievers lead to a significant increase in functional recovery and independence in daily life after an acute stroke.Cerebral venous and sinus thrombosis (CVST) comprises nearly 0.5-1 % of all stroke cases. CVST causes different neurological deficits depending on the sinus/cortical vein involved. CVST may cause death and dependency in 13.4 % of patients. CT/CT venography and MR/MR venography can be effectively used to diagnose and to follow up CVT cases. Anticoagulation with heparin is the most widely accepted therapy to prevent the expansion of the thrombus. Patients deteriorating despite heparinization and patients presenting with very severe neurological deficits must receive endovascular treatment. Endovascular methods include intrasinus infusion of thrombolytics or heparin, balloon angioplasty, mechanical thrombectomy or a combination of different techniques. There is a higher rate or recanalization with endovascular methods compared to other medical therapies.

摘要

深静脉血栓形成(DVT)是一种常见疾病,死亡率较高。对于近期形成血栓(<10 - 14天)的急性髂股静脉DVT患者,最有可能成功进行急性DVT的血管内治疗。血管内治疗选择包括:导管直接溶栓(CDT)、药物机械性导管直接溶栓(PCDT)、经皮抽吸血栓切除术(PAT)、腔静脉滤器保护、静脉球囊扩张和静脉支架植入。目前的实践表明,使用PCDT联合或不联合其他血管内方法以及针对每位DVT患者采取个体化方法具有很强的临床趋势。由于存在肺栓塞风险以及血栓切除装置对静脉瓣膜造成损伤,PMT尚未得到广泛认可。PAT最常作为一种辅助血管内技术,如球囊捣碎使血栓碎裂、球囊血管成形术、支架植入和腔静脉滤器置入。DVT的介入性血管内治疗有可能提供肺栓塞保护并预防血栓后综合征(PTS)。建议采用以患者为中心的个体化方法进行血管内DVT治疗,以优化理想的临床效果。

急性中风是60岁以上人群的主要死因,在15 - 59岁人群中是第五大死因。缺血性中风前30天的死亡率为20%,30%的幸存者将永久致残。处于治疗窗内的急性中风患者必须接受静脉注射重组组织型纤溶酶原激活剂(IVrtPA),除非存在禁忌症。在IVrtPA存在禁忌症或患者超出溶栓治疗窗的情况下,标准治疗是动脉内治疗。患者必须被转运至具备专用神经血管成像和介入神经放射学能力的综合中风中心。用于排除出血的非增强头部CT之后是专门用于显示是否存在可挽救的合理半暗带的成像研究。动脉内溶栓的主要优点是治疗窗延长、再通更早且更有效,以及由于溶栓剂剂量较低出血风险较小。与静脉/动脉内纤维蛋白溶解相比,机械取栓术有几个优点,包括再通更快且出血风险较小,尤其是在大动脉闭塞的情况下。美国心脏协会(ASA)指南推荐在机械取栓术中选择支架取栓器而非其他装置。与其他治疗相比,机械取栓术后更好的再通率和更小的梗死体积导致功能独立患者数量更多。最近发表的两项具有里程碑意义的研究,即SWIFT PRIME和MR CLEAN,表明动脉内治疗,尤其是使用新型支架取栓器,会使急性中风后功能恢复和日常生活独立性显著增加。

脑静脉和静脉窦血栓形成(CVST)占所有中风病例的近0.5 - 1%。CVST根据所涉及的静脉窦/皮质静脉导致不同的神经功能缺损。CVST可能导致13.4%的患者死亡和残疾。CT/CT静脉造影和MR/MR静脉造影可有效用于诊断和随访CVT病例。使用肝素进行抗凝是预防血栓扩展最广泛接受的治疗方法。尽管进行了肝素化治疗但病情仍恶化的患者以及出现非常严重神经功能缺损的患者必须接受血管内治疗。血管内方法包括静脉窦内注入溶栓剂或肝素、球囊血管成形术、机械取栓术或不同技术的联合应用。与其他药物治疗相比,血管内方法的再通率更高。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验